Applied therapeutics announces full enrollment in the registrational phase 3 arise-hf trial of at-001 in diabetic cardiomyopathy

New york, oct. 25, 2022 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced full enrollment in the phase 3 registrational arise-hf trial, studying at-001, a selective aldose reductase inhibitor, in patients with diabetic cardiomyopathy (dbcm).
APLT Ratings Summary
APLT Quant Ranking